PeerVoice Oncology & Haematology Video

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions

Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes

Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Krista Noonan, BSc, MD, FRCPC / Elizabeth R. Plimack, MD, MS, FASCO - Redefining the Standards of Care in RCC: Expert Insights to Translate Recent Advances to Clinical Practice

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma

Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma